A Clinically Relevant But Rarely Discussed Topic

The musculoskeletal consequences of recreational drug use are systematically underrepresented in clinical education and patient resources, despite affecting a substantial portion of the population seeking manual therapy and rehabilitation care. Practitioners encounter these effects regularly — in the form of unexplained muscle breakdown, accelerated joint degeneration, poor healing outcomes, and patterns of injury incongruent with reported activity levels. A working understanding of the tissue-level effects of common substances is therefore not merely academic; it is directly relevant to clinical reasoning, outcome prediction, and patient communication.

This article addresses the principal musculoskeletal effects of the most clinically significant recreational substances: cocaine, methamphetamine, MDMA, cannabis, opioids, and anabolic-androgenic steroids. Alcohol, given its prevalence and distinct physiological effects on healing, is addressed separately.

Stimulants: Cocaine and Methamphetamine

Cocaine produces acute and chronic musculoskeletal effects through several mechanisms. Its intense vasoconstrictive properties reduce perfusion to peripheral musculoskeletal tissues, impair nutrient delivery to healing tissue, and increase the risk of ischaemic compartment syndrome following exertion. The intense sympathomimetic response — elevated heart rate, hypertension, hyperthermia — places extreme metabolic demands on skeletal muscle. Repeated use is associated with significant muscle wasting due to impaired protein synthesis, chronic nitrogen loss, and disrupted sleep architecture.

Cocaine-associated levamisole contamination — levamisole is a veterinary anthelminthic used as a cutting agent — has been implicated in vasculitic syndromes affecting the skin, joints, and kidneys. The musculoskeletal presentation can mimic autoimmune arthritis, creating significant diagnostic confusion.

Methamphetamine produces profound neurotoxicity alongside severe skeletal muscle damage. Rhabdomyolysis — the rapid breakdown of skeletal muscle with release of myoglobin into the circulation — is a recognised complication of methamphetamine toxicity, particularly in the context of hyperthermia and agitation. Myoglobinuria causes acute kidney injury and, if severe, requires emergency hospitalisation. Chronic methamphetamine use results in a hypermetabolic state, severe malnutrition, profound muscle wasting, and impaired wound healing — the cumulative effect producing a physical deterioration dramatically disproportionate to the individual's stated age.

MDMA and Cannabis

MDMA (3,4-methylenedioxymethamphetamine) causes hyperthermia, hyponatraemia (from excessive fluid intake without electrolyte replacement), and intense serotonergic activation. In the musculoskeletal context, hyperthermia is the primary concern — core temperatures above 40°C rapidly produce rhabdomyolysis and direct muscle protein denaturation. Hyponatraemic states cause muscle cramping, weakness, and, in severe cases, cerebral oedema. Repetitive MDMA use is associated with serotonin syndrome risk when combined with other serotonergic agents, which can produce severe muscle rigidity, clonus, and hyperthermia.

Cannabis has a less acutely damaging direct musculoskeletal profile, though chronic heavy use is associated with reduced bone mineral density — an effect mediated through cannabinoid receptor signalling in osteoblasts and osteoclasts. Cannabis-associated hyperemesis syndrome, while primarily gastrointestinal, produces dehydration and electrolyte imbalance that impair muscle function. From a clinical perspective, cannabis's analgesic properties may mask injury severity, leading to inadequate rest and worsened tissue damage. The effect of cannabinoids on pain centralisation and descending inhibitory systems is an area of active research.

Opioids

Chronic opioid use produces several musculoskeletal consequences beyond the intended analgesic effect. Opioid-induced androgen deficiency (OPIAD) is a well-documented consequence of long-term opioid therapy — opioids suppress hypothalamic-pituitary-gonadal axis signalling, reducing testosterone and oestrogen production. The resulting hypogonadism produces reduced muscle mass, increased fat deposition, decreased bone density, fatigue, and impaired healing — effects that significantly compromise rehabilitation outcomes in chronic pain patients on long-term opioid therapy.

Paradoxical opioid-induced hyperalgesia — where chronic opioid use actually lowers pain thresholds — complicates the clinical picture in patients with musculoskeletal pain on long-term opioids. Clinicians should be alert to pain presentations that appear disproportionate to tissue findings in this population.

Anabolic-Androgenic Steroids

Anabolic-androgenic steroids (AAS) occupy a distinct category — used deliberately to enhance muscle mass and athletic performance rather than for recreational psychoactive effects. Their musculoskeletal consequences are well-characterised and clinically significant. AAS use accelerates muscle hypertrophy and strength development at a rate that substantially exceeds the adaptation capacity of the connective tissue — tendons, ligaments, and entheses — that support those muscles. The resulting mismatch produces markedly elevated rates of tendon rupture, particularly of the distal biceps, quadriceps, patellar, and Achilles tendons. These injuries frequently occur with little warning and at loads that would be benign in an equally trained natural athlete.

Long-term AAS use produces testicular atrophy, suppression of endogenous testosterone production, gynaecomastia, and — critically from a musculoskeletal perspective — premature closure of epiphyseal growth plates in adolescent users, producing stunted long bone growth. Cardiovascular complications (left ventricular hypertrophy, dyslipidaemia, hypertension) and hepatotoxicity are documented. Post-cycle, the withdrawal of supraphysiological androgen exposure produces a hypogonadic state that can persist for months to years, resulting in severe fatigue, depression, muscle wasting, and significantly impaired recovery.

Clinical note: AAS-associated tendon ruptures often require surgical repair. If you are a clinician palpating a large, apparently well-conditioned muscle belly in a patient presenting with acute tendon injury, AAS use should be considered in the differential — particularly in young males aged 18–35.

References & Further Reading

  1. Richards JR, et al. Rhabdomyolysis in the emergency setting. J Emerg Med. 2016;51(1):37–44.
  2. Rahnema CD, et al. Designer steroids — over-the-counter supplements and their androgenic component. Fertil Steril. 2015;103(1):15–19.
  3. Fronczak CM, et al. The insidious effects of illicit anabolic-androgenic steroids. Am J Mens Health. 2012;6(2):139–150.
  4. Vuong C, et al. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.